Preclinical Model to Guide Immunotherapeutic Development

Nov. 18-21

Barcelona, Spain

Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the delivery of two presentations at the 26^th EORTC-NCI-AACR Symposium, held in , discussing the creation of an innovative TumorGraft model (ImmunoGraft) specific to immune-modulating therapeutics and benefits of Champions' TumorGrafts® in guiding clinical development strategy.

Keren Paz

"There continues to be a need for improved models that enable researchers to better understand the clinical potential of therapeutics early in their development, ideally in the preclinical setting," said , Ph.D., chief scientific officer of Champions Oncology. "The findings presented at EORTC-NCI-AACR continue to demonstrate the advantages of our TumorGraft platform and our ability to create personalized mouse models for the exciting new class of immuno-oncology therapeutics. We look forward to presenting future case studies with our ImmunoGrafts at additional conferences in the year ahead."

Read the complete press release: http://prn.to/1F3F4M8